Cita APA (7a ed.)
Rasekh, E. O., Sherif, M. M., Ibrahim, N., Ibraheem, D., Ghareeb, M., & Elfishawi, S. (2026). BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia, 26(7), 447-456.
Cita Chicago Style (17a ed.)
Rasekh, Eman O., Menna M. Sherif, Nagwa Ibrahim, Dalia Ibraheem, Mohamed Ghareeb, y Sally Elfishawi. "BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia." Clinical Lymphoma, Myeloma & Leukemia 26, no. 7 (2026): 447-456.
Cita MLA (9a ed.)
Rasekh, Eman O., et al. "BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia." Clinical Lymphoma, Myeloma & Leukemia, vol. 26, no. 7, 2026, pp. 447-456.
Precaución: Estas citas no son 100% exactas.